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Abstract
Background: Every year millions of women around the world suffer from pregnancy, childbirth and postpartum
complications. Women who survive the most serious clinical conditions are regarded as to have experienced a
severe acute maternal complication called maternal near miss (MNM). Information about MNM cases may
complement the data collected through the analysis of maternal death, and was proposed as a helpful tool to
identify strengths and weaknesses of health systems in relation to maternal health care. The purpose of this study
is to evaluate the performance of a systematized form to detect severe maternal outcomes (SMO) in 20 selected
maternity hospitals from Latin America (LAC).
Methods: Cross-sectional study. Data were obtained from analysis of hospital records for all women giving birth
and all women who had a SMO in the selected hospitals. Univariate and multivariate adjusted logistic regression
models were used to assess the predictive ability of different conditions to identify SMO cases. In parallel, external
auditors were hired for reviewing and reporting the total number of discharges during the study period, in order to
verify whether health professionals at health facilities identified all MNM and Potentially life-threatening condition
(PLTC) cases.
Results: Twenty hospitals from twelve LAC were initially included in the study and based on the level of coverage,
11 hospitals with a total of 3,196records were included for the final analysis. The incidence of SMO and MNM
outcomes was 12.9 and 12.3 per 1,000 live births, respectively. The ratio of MNM to maternal death was 19 to 1, with a
mortality index of 5.1 %. Both univariate and multivariate analysis showed a good performance for a number of clinical
and laboratory conditions to predict a severe maternal outcome, however, their clinical relevance remains to be
confirmed. Coherence between health professionals and external auditors to identify SMO was high (around 100 %).
Conclusions: The form tested, was well accepted by health professionals and was capable of identifying 100 % of
MNM cases and more than 99 % of PLTC variables. Altered state of consciousness, oliguria, placenta accrete, pulmonary
edema, and admission to Intensive Care Unit have a high (LR+ ≥80) capacity to anticipate a SMO.
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Plain English summary
The objective of this study is to evaluate the performance
of a systematized form to detect severe maternal out-
comes in selected maternity hospitals from Latin America.
Data were obtained from analysis of hospital records
for all women giving birth and all women who had a
severe maternal outcome (SMO) in selected hospitals. A
cross sectional study was designed to evaluate and valid-
ate the new systematized form and the performance to
identify maternal near miss (MNM) and Potentially life-
threatening conditions (PLTC) cases. The incidence of
SMO and MNM outcomes was 12.9 and 12.3 per 1,000
live births, respectively. The ratio of MNM to maternal
death was 19 to 1, with a mortality index of 5.1 %. The
use of a systematized form showed a good performance
for a number of clinical and laboratory conditions to
predict a severe maternal outcome. The form tested, was
well accepted by health professionals and was capable of
identifying 100 % of MNM cases and more than 99 % of
PLTC variables. Altered state of consciousness, oliguria,
placenta accrete, pulmonary edema, and admission to
Intensive Care Unit have a high capacity to anticipate a
SMO.
Background
In 2015, the World Health Organization (WHO) esti-
mated more than 300,000 maternal deaths worldwide [1];
and around ten million women suffered from complica-
tions related to pregnancy, childbirth and postpartum
worldwide [2–8]. It is considered that women, who
survive the most serious clinical conditions have suffered
a severe acute maternal complication called maternal near
miss (MNM) [9–11]. Comprehensive studies concluded
that information on MNM is helpful to identify health sys-
tems’ strengths and weaknesses related to maternal health
care. MNM cases have many characteristics in common
with maternal deaths and could become a direct source of
information on the hurdles that women have to overcome
following an acute complication. Such cases may comple-
ment the information collected through maternal death
analysis [11–15]. Lack of reliable information to assess this
problem is a critical issue, whose gap has been partially
filled with information derived from two multicenter cross
sectional studies, one from Brazil [16] and the other
conducted by the WHO in 29 countries [17]. By the same
token, the Pan American Health Organization (PAHO)
proposed the development of a systematized form to
routinely collect and analyze data on maternal health and
quality of health care. This form particularly focuses on se-
vere maternal morbidity and mortality so Latin American
health facilities are more aware of the he current situation
of MNM cases.
The Perinatal Information System consists of basic
perinatal clinical records (PCR) with complementary
forms and charts and a software package for personal
computers that was developed by the Latin American
Center for Perinatology (CLAP) from WHO/PAHO and
is currently used by 28 countries from the Americas. A
standardized form and an application tool was added to
use as a data collection form for MNM. According to
WHO, a maternal near-miss case (MNM) is defined as
“a woman who nearly died but survived a complication
that occurred during pregnancy, childbirth or within
42 days of termination of pregnancy” and “potentially
life-threatening conditions” (PLTC) is an extensive
category of clinical conditions, including diseases that
can threaten a woman’s life during pregnancy and labor
and after termination of pregnancy. In practical terms,
women are considered near miss cases when they sur-
vive life-threatening conditions (i.e. organ dysfunction).
Additionally, severe maternal outcomes (SMO) are
maternal near miss cases and maternal deaths [18].
Therefore, the main purpose of this study was to
evaluate the introduction of a standardized form in obstet-
ric routinely practice, in order to collect information on
MNM and other Potentially life-threatening conditions
(PLTC) variables in LAC selected maternity hospitals. This
was done to know the predictive ability of PLTC variables
for the identification of severe maternal outcomes (SMO),
and to define their acceptance by health professionals
(HP).
Methods
In October 2012, CLAP summoned a group of regional
experts to develop an annex form, that would comple-
ment the PCR of the Perinatal Information System, based
on the definitions and standardized variables included in
“The WHO near-miss approach for maternal health” [18].
Once forms were defined and agreed upon (Fig. 1), pro-
cedure protocols developed, and manuals of operations
written, an invitation was sent through the WHO/PAHO’s
country offices to all Spanish-speaking countries in the
Americas. Ministries of health of 12 countries accepted to
participate in the study, with a total of participating 20
facilities, 19 that met the pre-defined requirement of
having 3,000 or more annual deliveries and one facility
with 1200 deliveries per year enrolled in the study as well.
This process finished in January 2013. In 2013, Nicaragua
hosted a training workshop targeted at hospital coordina-
tors responsible for conducting the pilot test at selected
facilities and obtaining approvals from local Ethics Institu-
tional Committees to carry out the study. All proposed
facilities were accepted, whether they regularly used or did
not use the PCR and the CLAP/PAHO’s SIP.
Hospital coordinators trained those professionals who
regularly assisted patients at their departments using the
training and dissemination modalities that best fitted
their context. Fourteen hospitals held workshops, while
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five organized briefings and/or seminars. When the
study ended, hospital coordinators submitted a final
standardized report to CLAP, using the “Survey Monkey”
survey format. Five external auditors, who were not
related with hospital coordinators, were responsible for
reviewing and reporting the total number of discharges
during the study period. For budgetary reasons, only five
external auditors were selected (countries were drawn)
to audit health facilities. Taking advantage of the prox-
imity of health facilities in Argentina and Paraguay, the
external reviewers hired for those countries, took under
their supervision two health facilities in each country.
Finally, these auditors supervised seven maternity hospi-
tals (two in Argentina, and Paraguay, one in Colombia,
Nicaragua and Uruguay). The objective of the external
auditing was to verify whether teams working at health
facilities identified PLTC/MNM variables and to confirm
which forms were adequately filled in.
The study population consisted of all women giving
birth at the participating maternity hospitals during the
study period. In addition, the study included all pregnant
or postpartum women or women within 42 days of
pregnancy termination, regardless of the mode of
delivery, and women admitted to the department of ob-
stetrics, surgery, emergency, gynecology, intermediate
and/or intensive care units due to any PLTC or MNM
condition. It was sufficient to check at least one of the
items of the form for MNM or PLTC to consider that as
a case (Fig. 1). Before analyzing the predictive ability of
each PLTC, a multiple imputation [19] was done to esti-
mate missing data for each PLTC. There were 41 vari-
ables with less than 5 % of missing values, five variables
with 5–35 % of missing values, and five variables (all
corresponding to laboratory values) with more than
35 % of missing values.
The predictive ability of each condition that could
potentially identify a case of SMO was assessed. A
univariate logistic regression model was used for such
assessment, and based on this; positive and negative like-
lihood ratios (LR) together with their 95 % confidence
intervals were calculated. Multivariate analyses were
performed separately for the three clinical conditions
most significantly associated with MNM and death:
hypertensive disorders, postpartum hemorrhage and
Fig. 1 Clinical Perinatal Record (reverse) MNM and PLTC variables
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infections. To this end, a stepwise selection was
performed for all variables related to each condition. In
all cases, interventions were excluded from the model
because it was not possible to establish a time relation-
ship, i.e., whether the intervention took place before or
after the occurrence of a SMO. Multivariate logistic models
were also adjusted for each of these three conditions in
order to estimate the likelihood of a SMO when more than
one PLTC occured concurrently. All analyses were con-
ducted using the SAS statistical software (version 9.3).
Results
The study was planned as a quick 1-month intervention
in each maternity hospital; all participating sites com-
pleted the study between March and June 2013. Twenty
hospitals from twelve countries participated in the study
(Additional file 1: Table S1). External auditors identified
the same number of MNM cases as those reported by
professionals who regularly provided care to women
(100 % agreement). For PLTC, there was also a 100 %
agreement in six maternity hospitals and a 91.2 % agree-
ment in the remaining facility (total: 99.3 %).
One hospital from Panama was excluded from analysis,
due to the fact that they only entered variables corre-
sponding to the complementary clinical record in the
study database. A total of 4,535 women were admitted in
the remaining 19 hospitals (deliveries + cases of hospital
admissions related to pregnancy or abortion with PLTC/
MNM). Four hundred forty-four cases of abortion with
SMO were excluded, for the reason that non complicated
abortions cases were not always admitted in the participat-
ing hospitals, so incidences of abortions with complicatios
over the total number of abortions could not be estimated.
In addition, 155 cases were excluded because the MNM
section had not been completed. The final sample con-
sisted of 3,936 records. In the study period, there were
6,225 births in the participating hospitals, resulting in
63 % coverage. Based on this, it was decided to include in
the analysis only those hospitals where coverage was equal
to or higher than 80 %, and this resulted in 11 hospitals
with 3,196 records (Fig. 2).
In the sample there were two maternal deaths and 37
cases of MNM, resulting in 39 cases of women with a
SMO (Table 1). The proportion of mothers aged 10–14
years old or older than 35 years old was higher in the
group of women with a SMO than in the overall sample.
This is also the case of women with no partners, women
without education, nulliparous women, those with only
one antenatal care visit or no antenatal care, those with
one or more previous cesarean-section (C-section), and
those with induced onset of labour or elective C-section
or with a delivery that ended in a C-section (Additional
file 1: Table S2).
PLTC cases were much more frequent in the group of
women with a SMO than in the overall sample, except
for neutrophilia with a left shift and SIRS. No differences
were observed in relation to pH <7.3, pulmonary
thromboembolism, uterine rupture, pneumonia, diabetic
ketoacidosis, and Thyrotoxicosis because no cases were
recorded (Additional file 1: Table S3). Perinatal outcomes
indicate that women with a SMO have a higher rate of
preterm births, fetal and neonatal deaths. There is also a
higher incidence of newborns with a birth weight of less
than 2,500 g and newborns admissions to the Neonatal
Intensive Care Unit (Table 2).
In relation to overall indicators, the incidence of SMO
and MNM was 12.9 and 12.3 per 1,000 live births,
respectively. The MNM index per mortality case was 19
to 1, with a mortality index of 5.1 %. Overall, 1 % (32/
3,168) of women were admitted to the ICU; 53.1 % of
them with a SMO (n = 17). In addition, 46 % of women
with a SMO were admitted to the ICU (17/37). The
univariate analysis regarding the diagnostic capacity of
PLTC for SMOs showed a high prediction of positive re-
sults (LR+ ≥20) for the following clinical criteria: altered
state of consciousness, oliguria and seizures. Laboratory
tests associated to a high LR+ included creatinine
≥1.2 mg/dL; platelet count <100,000 and GOT ≥ 70 U/L.
Conditions with a higher predictive efficacy when the
test is positive are placenta accreta, pulmonary edema,
HELLP syndrome, sepsis and eclampsia. In relation to
interventions, the following also have a LR+ ≥20: admis-
sion to the ICU, laparotomy and administration of blood
products. This group includes certain conditions with a
very high predictive and diagnostic capacity when posi-
tive (LR+ ≥80): altered state of consciousness, oliguria,
placenta accreta, pulmonary edema and admission to the
ICU (Additional file 1: Table S3).
An adequate performance (LR+ ≥10–19) was observed
in relation to clinical condition indicators, such as post-
partum hemorrhage, abruptio placentae, placenta praevia,
severe preeclampsia and infections, and in relation to
interventions, such as the administration of uterotonics to
treat postpartum hemorrhage and the administration of
antibiotics to treat infectious complications (Table 3). For
the multivariate analysis of hypertensive disorders of preg-
nancy, variables considered were those included in the
form for this condition. Women with altered state of con-
sciousness had almost a five-fold likelihood of developing
a SMO: adjusted odds ratio (OR): 4.48; 95 % confidence
interval (CI): 2.60–7.74. This is followed by a platelet
count lower than 100,000/mL (OR: 3.81, 95 % CI: 2.68–
5.43), LDH >600 U/L (OR: 2.64, 95 % CI: 1.66–4.20) and
creatinine ≥1.2 mg/dL (OR: 2.28, 95 % CI: 1.35–3.85). The
correspondent area under the ROC curve was 0.76.
As shown in Fig. 3, the association of more than one
of these indicators increases the likelihood of having a
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SMO. Thus, women with severe hypertension or severe
preeclampsia have a 12.8 % likelihood of developing a
SMO, and such probability increases to 47.5 % if they
also have eclampsia or abruptio placentae. Besides, it
increases to 84.3 % if they also have oliguria or altered
state of consciousness, and to 85.4 % if, in addition, they
have an altered laboratory test.
For postpartum hemorrhage, a laboratory value of
PaCO2 < 32 mmHg indicates a seven-fold increase in the
odds of developing a SMO (adjusted OR: 6.99, 95 % CI:
3.89–12.57). This is followed by a platelet count <100,000/
mL (adjusted OR: 6.02, 95 % CI: 4.19–8.64), altered state
of consciousness (adjusted OR: 4.88, 95 % CI: 2.69–8.83),
postpartum hemorrhage (adjusted OR: 2.79, 95 % CI:
1.88–4.12), hypotension (adjusted OR for SBP ≤90 mmHg:
2.29, 95 % CI: 1.60–3.29, and for HR >90 bpm: 1.61,
95 % CI: 1.16–2.21), with an area under the ROC
curve of 0.90. When there is an association of these
conditions, the likelihood of having a SMO in the
presence of a condition is 22.2 %, and it increases to
66.9 % if a woman is diagnosed with postpartum
haemorrhage, and to 76 % if she also has oliguria,
hypotension or an altered state of consciousness, that
increases to 98.4 % if they have any of the laboratory
tests with an altered value (Fig. 4).
For infections, also a laboratory value of PaCO2 <
32 mmHg indicates a higher than six-fold increase in
the odds of developing a SMO (adjusted OR: 6.29,
95 % CI: 3.52–11.24). This is followed by high biliru-
bin values (adjusted OR: 5.59, 95 % CI: 3.28–9.53),
altered state of consciousness (adjusted OR: 4.84,
95 % CI: 2.70–8.66), and pyelonephritis (adjusted OR:
3.29, 95 % CI: 1.67–6.46). Lower, but still significant values
were observed in relation to infections, hypotension and
tachycardia. The correspondent area under the ROC
Table 1 Maternal Deaths (MD), Maternal Near Miss (MNM), and
Severe Maternal Outcomes (SMO) by country
Country Number of
hospitals
Live births MD MNM SMO
(MD +MNM)
Argentina 3 762 0 2 2
Colombia 1 334 0 3 3
Dominican Republic 1 133 0 3 3
Ecuador 1 228 0 2 2
Honduras 2 613 1 10 11
Nicaragua 1 477 0 4 4
Paraguay 1 334 1 2 3
Peru 1 315 0 11 11
Total 11 3196 2 37 39
Fig. 2 Study flowchart
Table 2 Perinatal results
All babies
n/N (%)
Babies from women with SMO
n/N (%)
Preterm birth 414/3113 (13.3) 17/39 (43.6)
Stillbirth 35/3064 (1.1) 5/39 (12.8)
Neonatal death 27/1863 (1.5) 4/18 (22.2)
Admission to SCBU 329/2520 (13.1) 10/25 (40.0)
Birth weight
<1000 g 18/3053 (0.6) 2/35 (5.7)
1000–1499 g 31/3053 (1.0) 5/35 (14.3)
1500–2499 g 243/3053 (8.0) 5/35 (17.1)
>2500 g 2761/3053 (90.4) 22/35 (68.9)
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Table 3 Univariate analysis (with data imputation) of PLTC for SMO
Variable LR+ (95 % CI) LR- (95 % CI) AUCa
Clinical parameters Altered state of consciousness 101.2 (28.2–362.6) 0.9 (0.8–1.0) 0.56
Oliguria 80.9 (24.4–268.4) 0.9 (0.8–1.0) 0.56
Seizures 40.5 (7.6–214.5) 0.9 (0.9–1.0) 0.53
SBP ≥160 mmHg 8.5 (5.3–13.8) 0.7 (0.6–0.9) 0.65
Temperature >38 °C or <36 °C 7.6 (4.3–13.5) 0.8 (0.6–0.9) 0.61
SBP ≤90 mmHg 6.9 (3.9–12.3) 0.7 (0.5–1.0) 0.66
DBP ≥110 mmHg 6.7 (3.5–12.8) 0.8 (0.7–1.0) 0.59
HR >90 bpm 3.9 (2.9–5.2) 0.5 (0.4–0.7) 0.71
DBP ≤60 mmHg 3.3 (2.4–4.5) 0.6 (0.4–0.8) 0.68
RR >20 rpm 2.0 (1.2–3.4) 0.8 (0.7–1.0) 0.57
Laboratory parameters Creatinine ≥1.2 mg/dL 48.6 (18.6–127.0) 0.8 (0.7–1.0) 0.58
Platelet count <100 000/mL 35.2 (13.4–92.8) 0.6 (0.4–1.0) 0.67
AST ≥70 U/L 22.3 (10.3–40.4) 0.8 (0.7–1.0) 0.60
WBC >12 000 or <4000 /mL 2.2 (1.5–3.2) 0.7 (0.6–0.9) 0.61
Band neutrophils >10 % (left shift) 1.6 (0.4–6.1) 1.0 (0.9–1.0) 0.51
LDH >600 U/L – – –
Bilirubin total > 1.2 mg/dL – – –
pH <7.3 – – –
PaO2/FiO2 < 400 mmHg – – –
PaCO2 < 32 mmHg – – –
Conditions Placenta accrete 161.9 (15.0–1748.7) 0.9 (0.9–1.0) 0.53
Pulmonary edema 121.4 (20.9–706.6) 0.9 (0.8–1.0) 0.54
HELLP syndrome 52.0 (23.9–113.0) 0.8 (0.7–0.9) 0.61
Sepsis 40.5 (12.7–128.8) 0.9 (0.8–1.0) 0.55
Eclampsia 23.1 (5.0–107.8) 1.0 (0.9–1.0) 0.52
Postpartum hemorrhage 19.5 (11.6–32.7) 0.7 (0.5–0.8) 0.66
Abruptio placentae 19.4 (9.8–88.4) 0.9 (0.8–1.0) 0.55
Other infections 16.8 (8.4–33.3) 0.8 (0.6–1.0) 0.62
Severe preeclampsia 13.9 (9.1–21.3) 0.6 (0.5–0.8) 0.69
Placenta praevia 11.0 (3.4–35.4) 0.9 (0.8–1.0) 0.53
Pyelonephritis 8.6 (0.9–83.3) 1.0 (0.4–2.0) 0.52
Severe hypertension 6.0 (1.5–24.3) 1.0 (0.9–1.0) 0.52
Endometritis 5.0 (0.7–37.5) 1.0 (0.9–1.0) 0.51
SIRS 1.0 (0.5–2.2) 1.0 (0.9–1.1) 0.50
Uterine rupture – – –
PTE – – –
DVT – – –
Pneumonia – – –
Diabetic ketoacidosis – – –
Thyroid storm – – –
Interventions Admission to the ICU 91.7 (49.4–170.3) 0.6 (0.4–0.7) 0.72
Laparotomy (excluding C-section) 50.6 (17.3–147.8) 0.9 (0.8–1.0) 0.56
Administration of blood products 34.0 (3.6–323.0) 0.5 (0.1–2.9) 0.74
Uterotonics to treat hemorrhages 15.0 (9.5–23.5) 0.6 (0.5–0.8) 0.68
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curve was 0.84. The likelihood of a SMO increases to
3.3 % when there is also hypotension or fever. If
these women are also diagnosed with sepsis, endo-
metritis or other infections, such likelihood increases
to 21.9 %. When women also have a reduced state of
consciousness, their likelihood of having a SMO
increases to 80.6 and to 85.1 % if they further have
altered laboratory tests (Fig. 5).
Discussion
The implementation of MNM surveillance at selected
hospitals in Latin America is the first step towards the
guidance on how to use such tool to improve maternal
health. Based on the same guiding principle used for
mortality analysis systems, this form is expected to
provide health services with systematized information
and become a validated tool to monitor potentially life-
threatening conditions and identify hurdles that prevent
the provision of an adequate and timely care. Such kind
of multicenter surveillance was already successfully tried
at least twice in Latin America [16] and again proved to
be feasible and sensible to identify cases deserving
special timely and adequate care.
The form used to identify MNM cases achieved a
100 % case identification in all health facilities. Almost
all clinicians participating in the study indicated that iden-
tification may be helpful for managers and epidemiologists
and for the prevention of potential cases (if correctly
audited). There was less agreement on the form’s useful-
ness for the case clinical management, since parameters
show such serious conditions that no further interventions
would be required to improve the patient’s diagnosis. In
addition, most forms were filled out retrospectively after
the case resolution. One potential selection bias during
the data collection was the fact that a total of 155 cases
were excluded because the MNM section had not been
completed. However, in the hospitals that hired external
auditors the missing data were for PLTC variables but not
for SMO cases. The latter are most of the cases that were
admitted to intensive care and the missing data in this
patients were scarce,
In relation to the PLTC form, it proved useful to identify
almost all cases since in only one health facility the exter-
nal auditor identified more events than those reported by
the attending health care providers. Although it will be
necessary to adjust cut-off points for some of the
variables, in many cases attending professionals did not
comply with the completion requirements indicated in the
manual and clinical records themselves. This was particu-
larly the case with the following variables: SBP <90 mmHg,
DBP <60 mmHg, HR >90 bpm, RR >20 rpm, WBC >12
000/mL and band neutrophils >10 %.
Some coordinators indicated that the PLTC form was
useful because, when completed prospectively, it allowed
to warn on the complications at an earlier stage and to
take corrective actions. This was particularly the case at
Table 3 Univariate analysis (with data imputation) of PLTC for SMO (Continued)
Use of IV antibiotics to treat infectious complications 14.4 (6.1–34.1) 0.5 (0.3–1.1) 0.72
Removal of retained products of conception 6.1 (2.6–14.4) 0.9 (0.8–1.0) 0.55
Manual removal of the placenta 6.1 (1.0–37.4) 0.9 (0.4–2.0) 0.53
Suture of complicated tears 5.1 (1.3–20.4) 1.0 (0.9–1.0) 0.52
Uterine artery ligation/embolization – – –
aArea under curve
Fig. 3 Cumulative estimated probability of SMO in hypertensive disorders of pregnancy
De Mucio et al. Reproductive Health  (2016) 13:134 Page 7 of 10
the health care facilities where deliveries are attended by
professional midwives, nurses and/or general practi-
tioners. However, in most places, the form was completed
retrospectively, once the case was closed. At these hospi-
tals, coordinators also stated that the form had not been
useful for clinicians dealing with the patient.
Some professionals indicated that certain variables
included in the PLTC form are so severe that, when
identified, the patient is already managed as MNM. This
was especially indicated for certain laboratory tests (pH
<7.3, PaO2/FiO2 < 400 mmHg, PaCO2 < 32 mmHg). In
addition, these tests had been requested due to the
patient’s severe condition, since they are not routinely
used. This is confirmed by the fact that more than 35 %
of data were missing for five variables (all related to
these laboratory tests).
The prevalence of MNM at the 11 maternity hospitals
that provided data to the study was 12.9 per 1,000 live
births. These values are closer to those reported by the
WHO study (13.1 per 1,000 live births) for countries
with very high maternal mortality ratios [17] than to
those reported for all regions (8.3 per 1,000 live births)
or for Latin America alone (8.3 per 1,000 live births data
not published).
Univariate analyses on the diagnostic capacity of
PLTC for SMO were very high (LR+ ≥80) for clinical
conditions such as altered state of consciousness and
oliguria, for conditions such as placenta accreta and
pulmonary edema, and for interventions such as
admission to the ICU. In general, laboratory tests also
had an adequate performance when positive (LR+ 20–79).
However, these were the PLTC indicators with the
highest percentage of missing data (between 5 % for
platelet count <100,000/mL and 46 % for PaO2/FiO2 <
400 mmHg); therefore, data imputation was used as a stat-
istical technique for analysis. Given the pragmatic nature
of the study, some tests, which are considered to have a
high cost or are associated with morbidity (e.g., arterial
blood collection) were not requested routinely for all
women, only for those who had a severe condition. In
addition, all hospitals, except one, retrospectively com-
pleted forms, many times upon the patient’s discharge,
Fig. 4 Cumulative estimated probability of SMO in postpartum hemorrhage
Fig. 5 Cumulative estimated probability of SMO in infection
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transfer or death. Some PLTC possibly had more chances
of being detected and recorded in women with MNM
than in those who did not have MNM, so their diagnostic
capacity may have been overestimated. All these reasons
call for caution at the time of making conclusions based
on these results.
For multivariate analyses, all PLTC in the form that
could have been related to the three most common condi-
tions were selected: hypertensive disorders, postpartum
hemorrhage and infections. Variables related to clinical
interventions in this exploratory model were not included
because, given the form characteristics and variable collec-
tion modality, it was not possible to establish a time
relationship, i.e., whether the intervention occurred before
or after the MNM. This is one of the study limitations
since some variables (cesarean section, admission to the
ICU, laparotomy and administration of blood products)
show a high association in the univariate analyses, as
reported by other authors [20].
For multivariate exploratory analyses where two or
more PLTC occur concurrently, variables were se-
lected in advance based on the logical sequence of
their clinical presentation and/or on a diagnosis or
management algorithm. Thus, for example, postpar-
tum hemorrhage shows an increased probability of
SMO if conditions such as placenta praevia, placenta
accreta or early abruptio placentae are diagnosed in
advance (during antenatal care visits) or intrapartum;
such probability increases in the presence of a confirmed
postpartum hemorrhage. If during clinical monitoring, it
is confirmed that such woman has reduced urinary output
per minute (oliguria) or has clinical signs of arterial
hypotension or a reduced state of consciousness, this like-
lihood increases even more, suggesting the initiation of a
hypovolemic shock, which worsens if laboratory tests are
also altered. We are aware that other combinations may
have also been explored. However, we opted to
prioritize the clinical presentation and management
criterion for each condition so as to prevent possible
spurious associations due to multiple testing, on one
side, and to assess the clinical usefulness of the tool,
on the other.
Lastly, cases of abortion were excluded from the
analysis because not all women with uncomplicated
abortions were admitted to participating hospitals. In
addition, in some countries, cases of complicated abor-
tions were admitted to reference hospitals which did not
participate in the study. Given these reasons, it is not
possible to estimate the incidence or contribution of
abortion complications in general analyses. This is a
major limitation for result generalization because unsafe
abortion complications are still one of the leading causes
of maternal deaths in the region, and an analysis and bet-
ter understanding of abortion causes and determinants,
and associated morbidities in surviving women, are a
priority for public health planners and managers.
Conclusions
The form tested was well accepted by health professionals.
It was capable of identifying 100 % of MNM cases and
more than 99 % of PLTC variables. Almost all clinicians
participating in the study indicated that it could be helpful
for managers and epidemiologists and for the prevention
of potential cases (if correctly audited). Some PLTC vari-
ables should be reviewed to adjust cut-off points so as to
improve its clinical usefulness.
Some professionals indicated that certain variables
included in the PLTC form are so severe that, when
identified, the patient is already managed as a case of
MNM. This was especially indicated for certain labora-
tory tests (pH <7.3, PaO2/FiO2 < 400 mmHg, PaCO2 <
32 mmHg). In addition, these tests had been requested
because of the patient’s severe condition, since they are
not routinely used. This is confirmed by the fact that
more than 35 % of data were missing for five variables
(all related to these laboratory tests). Therefore, some
PLTC variables should be reviewed to adjust cut-off
points so as to improve its clinical usefulness. Altered
state of consciousness, oliguria, placenta accrete,
pulmonary edema, and admission to ICU have a high
(LR+ ≥80) capacity to anticipate a SMO.
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